Healthpeak Properties, Inc. Q3 FY2026 earnings call

• Outpatient Medical Strength: Management highlighted that cost pressures are driving health systems toward outpatient delivery, validating HealthPeak’s strategic position. The company created the leading platform in this sector following its merger three years ago.
• Life Science Recovery: The firm is outperforming sector peers, entering the recovery as the only company growing its footprint. Occupancy gains are driven by strategic hires, unencumbered real estate assets, and liquidity.
• Strategic Acquisitions: HealthPeak closed nearly $2 billion in stabilized sales/recaps earlier in the year at a 6% cap rate. Three new life science acquisitions were announced, leveraging the company's existing footprint to create a "network effect" and competitive advantage.
• Janus Living Expansion: The partnership model has scaled from two to 13 operating partners, driving proprietary acquisition flow. Since IPO, HealthPeak has closed $2.2 billion in acquisitions with NOI trending in line or ahead of underwriting.
• Operational Efficiency: Management emphasized focusing on bottom-line cash flow rather than "same store" metrics, which they view as misleading due to CapEx and pool movements. They prioritize net absorption, retention, and releasing spreads.

• Outpatient Medical: Total occupancy reached 90.3% (up sequentially on a comparable basis). The segment executed 846,000 square feet of leases with strong retention of 81.7%. Cash releasing spreads were approximately 5% above historical averages.
• Life Science: Total occupancy increased by 130 basis points sequentially to 79.8%, representing a 270 basis point year-to-date gain. The segment executed 480,000 square feet of leases in the quarter, its strongest performance in over a year.
• Senior Housing (Janus Living): Delivered same-store NOI growth of 26% and total revenue growth of 78%. Entry fee sales hit an all-time high for the quarter. The portfolio expanded significantly through acquisitions.

• FFO Adjusted: Raised guidance for the third consecutive quarter by two cents at the midpoint, now set at $1.76 to $1.78 per share.
• Same Store NOI Growth: Increased midpoint guidance by 50 basis points to a range of 0.5% to 2.0%. This includes:
  • Outpatient Medical: Raised by 25 basis points to 2.5% to 3%.
  • Lab/Life Science: Raised by 100 basis points to a decline of 3% to 6%.
  • Senior Housing: Raised by 250 basis points to 16% to 19%.
• Drivers: The updates reflect stronger leasing velocity across the portfolio, delayed timing of dispositions, and robust operating performance year-to-date.

• Interest Rate Volatility: Borrowing costs have increased due to Treasury yields, impacting refinancing costs for $1.4 billion in maturities due in 2027.
• Life Science Downturn Legacy: The sector suffered a severe downturn (loss of 2,500 basis points of occupancy), and while recovering, it takes time for lease executions to convert to cash rent due to build-out periods.
• Capital Market Constraints: Capital availability in life science has shifted from abundant to severely constrained, though this creates buying opportunities for HealthPeak.
• Refinancing Risk: The company faces higher refinancing costs compared to their current ~3% debt maturity rates, requiring proactive management of the balance sheet.

Q: Analyst asked about the pipeline for life science acquisitions, noting HealthPeak is a unique buyer given the market downturn. / A: CEO Scott Brinker explained that current opportunities allow them to buy assets that are both cheap and strategic, unlike typical trade-offs. They have a pipeline of over $1 billion in acquisitions that fit into existing campuses. The strategy involves buying non-leasing assets to lease up using their tenant network, with significant traction already seen on 70% of acquired vacancy before formal closing. This approach provides a margin of safety and upside as rents recover.

Q: Analysts inquired about the timeline for new leases to contribute to NOI and whether the lab business is at an inflection point. / A: CFO Kelvin stated that lease executions typically require 12 to 15 months to flow into NOI due to build-out and free rent periods. However, with 130 basis points of occupancy capture last quarter and 270 basis points year-to-date, the company is positioned for NOI growth as these leases commence. The focus remains on total occupancy gains to drive future earnings.

Q: Analyst questioned why HealthPeak adds more vacancy exposure when already ~80% occupied, asking about specific asset positioning. / A: CEO Brinker argued that local markets are ecosystems, not isolated assets. Buying core assets at 9-10% stabilized yields offers development-like returns with less risk. He distinguished the new acquisitions from existing properties by size and user type (e.g., larger floor plates for different users) and noted that acquiring adjacent properties strengthens the entire local footprint, making HealthPeak the "easy button" for tenants.

Q: Analyst asked if AI and robotics demand is incremental or just absorbing difficult-to-lease space. / A: SVP Scott Bohn clarified that biotech still comprises over 75% of the pipeline, but AI/robotics demand is significant, particularly in San Francisco. This demand is largely incremental, taking space in shell condition or previously misallocated buildings, often at lower TI costs. It also removes speculative supply from the market that might otherwise compete with traditional lab users.

Q: Analyst asked about the composition of the debt maturity profile and capital needs for 2027. / A: CFO Kelvin detailed that $1.4 billion matures in 2027, with $1.1 billion due in Q1. To manage this, they secured $900 million in delayed draw term loans priced at SOFR + 80 bps, which is cheaper than current bond issuance. They expect CapEx to remain consistent with past years, supporting leasing activities without dramatic increases.